spacer
home > pmps > spring 2019 > the impact of falsified medicines
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

The Impact of Falsified Medicines

In recent years, the number of falsified and counterfeit medications infiltrating the supply chain has become a growing problem for global health organisations and pharmaceutical manufacturers. Not only have there been cost implications, but there are also huge risks to patient safety.

The WHO references illegitimate medications as substandard and falsified medical products, with falsified medicines defined as “medical products that deliberately/ fraudulently misrepresent their identity, composition, or source” (1).

According to the WHO, about one in 10 pharmaceutical products in low and middle income countries are either substandard or falsified (2). The WHO also reported that, as of November 2017, “20 global medical product alerts and numerous regional warnings” had been issued, with “technical support provided in more than 100 cases” (2).

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Neil Piper is an Auto ID expert and business consultant with over 25 years’ experience working predominantly in the retail and healthcare sectors. He is skilled in GS1 International Society of Blood Transfusion standards, barcode technologies (printing and scanning), radio frequency identification, electronic product code information services, and regulatory compliance (FMD, unique device identification, both FDA and EU medical devices regulation/in vitro diagnostic medical devices, UK Medicines and Healthcare products Regulatory Agency GS1 compliance, and more). Neil is currently redrafting Information Standards Board (ISB) 1077 and ISB 0108 standards to comply with NHS digital requirements. He has provided consultancy to numerous NHS trusts and pharmaceutical and medical device suppliers.
spacer
Neil Piper
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

3P Biopharmaceuticals receives FDA approval

[Pamplona, September 16th, 2019] 3P Biopharmaceuticals (3P), a leading Contract Development and Manufacturing Organisation (CDMO) specialized in process development and GMP manufacturing of biologics, receives FDA approval after completing the Pre-Approval Inspection (PAI) conducted at the 3P drug substance manufacturing facility.
More info >>

White Papers

ECCRT

ECCRT

The European Centre for Clinical Research Training (ECCRT) is a professional clinical research training provider focusing on the transfer of implementable knowledge for the day-to-day activities of our participants whether being new to the industry, starters on the job, or seasoned professionals. Our mission is to facilitate Clinical Research professionals to excel in their job for the benefit of patients. We aim to achieve this by providing clinical research professionals with competencies to develop new therapies for patients quicker & more efficiently, without jeopardizing quality and safety.
More info >>

 
Industry Events

World Vaccine Congress Europe

18-21 October 2020, Barcelona, Spain

The World Vaccine Congress is an award-winning series of conferences and exhibitions that have grown to become the largest and most established vaccine meeting of its kind across the globe. Our credibility is show through the prestigious scientific advisory board that spend months of hard work creating a new and topical agenda, year on year.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement